Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paritaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paritaprevir SCHEMBL29359149 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061958 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3061962 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3069969 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL3069964 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18713503 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL16541443 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL18923192 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL19286688 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 | |
| Paritaprevir SCHEMBL20145316 | 1.00 | CTSB (0.45) | CTSBADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201237-A1 | RESPONSE-GUIDED HCV THERAPY | EMORY UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201237-A1 | RESPONSE-GUIDED HCV THERAPY | EIF2AK2, ADAR, IFNAR1 | CTSB 266/4885ADRB3 4174/4885ADRA2B 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.